NEW
Stock Screener with Intrinsic Value
Alnylam Pharmaceuticals, Inc. (ALNY)
Last Price$238.0(1.1%)
Market Cap$30.1B
WACC
7.8%
Cost of Equity
8.0%
Cost of Debt
2.7%
Debt to Equity
4.3%
Beta
1.0
Stock quality
6/10
Good
ALNY WACC
Crunching data... Almost there!
Best stock ideas on the market right now
With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.
ALNY Cost of Equity
Crunching data... Almost there!
ALNY vs Peer Set: Discount Rate Comparison
WACC
Cost of Equity
General
Discount rate
financials
Company name
Revenue growth
EPS growth
Net Income margin
Alnylam Pharmaceuticals, Inc.ALNY
7.8%
76.2%
(62.2%)
(24.1%)
Median Peer Set
7.9%
13.1%
(4.3%)
25.4%
Moderna, Inc.MRNA
10.8%
(64.4%)
N/A
(68.8%)
Genmab A/SGMAB
8.7%
15.7%
711.2%
26.4%
Incyte CorporationINCY
8.0%
8.9%
74.5%
16.2%
BioNTech SEBNTX
8.0%
(77.4%)
(89.7%)
24.4%
Vertex Pharmaceuticals IncorporatedVRTX
7.9%
10.5%
8.3%
36.7%
Novo Nordisk A/SNVO
7.9%
34.5%
(21.9%)
36.0%
United Therapeutics CorporationUTHR
7.8%
20.2%
31.7%
42.3%
Regeneron Pharmaceuticals, Inc.REGN
7.7%
7.8%
(8.5%)
30.1%
BeiGene, Ltd.BGNE
4.5%
73.7%
(56.5%)
(35.9%)
argenx SEARGX
negative
198.6%
(60.5%)
(24.1%)
Explore more intrinsic value tools hub for ALNY
Peter Lynch Fair Value
Margin of safety
Reverse DCF
Relative Value
DCF value calculator
Ben Graham Fair Value
Intrinsic Value
Peter Lynch charts
Earnings growth model
Earnings Power Value
Loved by
investors
worldwide
investors
worldwide
10K+
Investors
use our platform
#1
Top value investing hub
with all necessary tools
1K+
Experienced investors
in our community
4.9
Average rating across
all rating platforms
FAQ
What is Alnylam Pharmaceuticals, Inc.'s discount rate as of Jan 10, 2025?
As of Jan 10, 2025, Alnylam Pharmaceuticals, Inc.'s discount rate is 7.77%. This rate is determined based on the weighted average cost of capital (WACC) and the cost of equity, factoring in Alnylam Pharmaceuticals, Inc.'s capital structure and risk profile.
What is Alnylam Pharmaceuticals, Inc.'s weighted average cost of capital (WACC)?
Alnylam Pharmaceuticals, Inc.'s WACC as of Jan 10, 2025, is 7.77%. This value is calculated by blending the cost of debt and cost of equity, reflecting the company’s overall cost of financing its operations.
What is Alnylam Pharmaceuticals, Inc.'s cost of equity?
Alnylam Pharmaceuticals, Inc.'s cost of equity is 8.0%, as of Jan 10, 2025. This is the return that shareholders expect based on the stock's risk level and market conditions, used to calculate the discount rate for valuing future cash flows.